Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said that is ending its commercialization agreement with Quintiles, which was announced in 2011 and, for the time being, will manufacture the product for Chiesi.
Germany, where Bronchitol was launched in in 2012, and the UK, where the product launched in 2013, account for over 95% of European sales, according to the company.
Pharmaxis CEO Gary Phillips commented, “We are extremely pleased to have Chiesi as a distributor in these key European countries as well as in the United States, where an agreement was signed in December 2014. In Chiesi, Pharmaxis now has a single, experienced and respected partner working on Bronchitol in key markets where it will be sold as part of Chiesi’s cystic fibrosis portfolio.”
Read the Pharmaxis press release.
